checkAd
    Startseite > Aktien > Vivoryon Therapeutics > Nachrichten
    Vivoryon Therapeutics Aktie
    0,7910
     
    EUR
    -3,77 %
    -0,0310 EUR
    Letzter Kurs 26.04.24 Tradegate
    0,7790
     
    EUR
    710 STK
    Geldkurs 26.04.24
    0,8030
     
    EUR
    690 STK
    Briefkurs 26.04.24
    ISIN: NL00150002Q7 · WKN: A2QJV6 · SYM: 05Y · Niederlande

    Neueste Nachrichten

    Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates
    24.04.24 · globenewswire · Vivoryon Therapeutics
    Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024
    16.04.24 · globenewswire · Vivoryon Therapeutics
    Vivoryon Therapeutics N.V. Announces Changes to Board Composition
    15.03.24 · globenewswire · Vivoryon Therapeutics
    wO Börsenlounge: Super Micro | Tesla | BYD - ist bei Ferrari der Tank leer?
    04.03.24 · Markus Weingran · Bayer
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 04.03.2024
    04.03.24 · wO Chartvergleich · Myriad Genetics
    Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease
    04.03.24 · globenewswire · Vivoryon Therapeutics
    Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024
    08.01.24 · globenewswire · Vivoryon Therapeutics
    Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023
    28.11.23 · globenewswire · Vivoryon Therapeutics
    Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference
    07.11.23 · globenewswire · Vivoryon Therapeutics
    Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision
    26.10.23 · globenewswire · Vivoryon Therapeutics
    Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to Proceed at Highest Investigated Dose
    23.10.23 · globenewswire · Vivoryon Therapeutics
    Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Event with Key Opinion Leaders
    17.10.23 · globenewswire · Vivoryon Therapeutics